Jeffrey Tice, MD
Associate Professor, Department of Medicine (General Internal Medicine), UCSF
Cancer Center Program Memberships
Breast OncologyResearch Summary
My non-clinical work focuses on developing and evaluating risk assessment tools for breast cancer and using those tools to efficiently use screening technologies and preventive therapies to decrease the burden of breast cancer in our community.
I also perform technology assessments and support cost-effectiveness modeling and budget impact analyses for new medications, medical devices, and health system interventions for the Institute for Clinical and Economic Review.
Education
Dartmouth College, Hanover, NH, BA, 06/1983, Math; Philosophy
San Francisco State University, 05/1989, Pre-medical classed
University of California, San Francisco, MD, 06/1994, Medicine
University of California, San Francisco, 06/1997, Internal Medicine
University of California, San Francisco, Postdoctoral, 06/1999, Research/Epidmiology
Professional Experience
-
1984-1986
Peace Corps Volunteer, Bangassou, Central African Republic -
1987 - 1992
Programmer/Analyst III, Department of Epidemiology, University of California, San Francisco -
1999-2004
Assistant Adjunct Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco -
2005-2011
Assistant Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco -
2012-present
Associate Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
Honors & Awards
- 2013
UCSF Research Mentoring Award - 2009
Society of General Internal Medicine- CA Region- Outstanding Clinician Investigator Award - 2003
Robert Crede Award for Clinical Research, UCSF Division of General Internal Medicine - 2002-2004
Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Faculty Scholar - 1994
Alpha Omega Alpha, UCSF - 1990-1994
Regents Scholarship, UCSF - 1983
Summa Cum Laude, Dartmouth College - 1982
Phi Beta Kappa, Dartmouth College - 1979-1983
Rufous Choate Scholar, Dartmouth College - 1979-1983
IBM Thomas J. Watson Scholar
Selected Publications
- Tice JA, Campbell JD, Synnott PG, Walsh JME, Kumar VM, Whittington M, Adair E, Rind D, Pearson SD. The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma. J Manag Care Spec Pharm. 2019 May; 25(5):510-514.
View on PubMed - Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E. A response to "Personalised medicine and population health: breast and ovarian cancer". Hum Genet. 2019 Mar; 138(3):287-289.
View on PubMed - Tice JA, Bissell MCS, Miglioretti DL, Gard CC, Rauscher GH, Dabbous FM, Kerlikowske K. Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Res Treat. 2019 Jun; 175(2):519-523.
View on PubMed - Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. JAMA Netw Open. 2019 Feb 01; 2(2):e190035.
View on PubMed - Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, Chapman RH, Kumar V, Carlson JJ. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. CNS Drugs. 2018 Dec; 32(12):1145-1157.
View on PubMed - Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. JAMA Pediatr. 2018 Dec 01; 172(12):1161-1168.
View on PubMed - Ozanne E, Karliner LS, Tice JA, Haas JS, Livaudais-Toman J, Pasick RJ, Kaplan CP. An Intervention Tool to Increase Patient-Physician Discussion of Lifestyle Risk Factors for Breast Cancer. J Womens Health (Larchmt). 2018 Sep 15.
View on PubMed - Braithwaite D, Miglioretti DL, Zhu W, Demb J, Trentham-Dietz A, Sprague B, Tice JA, Onega T, Henderson LM, Buist DSM, Ziv E, Walter LC, Kerlikowske K. Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med. 2018 Apr 01; 178(4):494-501.
View on PubMed - Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA. 2017 08 22; 318(8):748-750.
View on PubMed - Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, Tice JA, Ziv E, Kerlikowske K, Cummings SR. Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. Breast Cancer Res Treat. 2017 Nov; 166(2):603-612.
View on PubMed - Tice JA, Kerlikowske K. Supplemental Breast Cancer Screening: A Density Conundrum. J Gen Intern Med. 2017 06; 32(6):593-594.
View on PubMed - Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. J Natl Cancer Inst. 2017 01; 109(5).
View on PubMed - Ziv E, Tice JA, Sprague B, Vachon CM, Cummings SR, Kerlikowske K. Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. PLoS One. 2017; 12(1):e0168601.
View on PubMed - Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL. Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer. J Natl Cancer Inst. 2017 05; 109(5).
View on PubMed - Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb; 118(2):220-225.
View on PubMed - Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JW, Tice JA, Vachon CM, Cummings SR, Kerlikowske K, Ziv E. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat. 2016 Oct; 159(3):513-25.
View on PubMed - Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman D, Bibbins-Domingo K. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 2016 Aug 16; 316(7):743-53.
View on PubMed - Reed SJ, Shore KK, Tice JA. Effectiveness and Value of Integrating Behavioral Health Into Primary Care. JAMA Intern Med. 2016 05 01; 176(5):691-2.
View on PubMed - Dallal CM, Lacey JV, Pfeiffer RM, Bauer DC, Falk RT, Buist DS, Cauley JA, Hue TF, LaCroix AZ, Tice JA, Veenstra TD, Xu X, Brinton LA. Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B ~ FIT Cohort. Horm Cancer. 2016 Feb; 7(1):49-64.
View on PubMed - Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med. 2016 Jan; 176(1):65-73.
View on PubMed